Viking Therapeutics, Inc. (NASDAQ:VKTX) was mentioned by Jim Cramer in a recent lightning round, comparing it unfavorably to Eli Lilly. The company focuses on therapies for metabolic and endocrine disorders, but its stock has declined by nearly 23% since, following a drop due to trial data on its anti-obesity drug.

Despite potential as an investment, Viking Therapeutics, Inc. (NASDAQ:VKTX) stock took a hit after patients in a trial dropped out due to negative effects of its anti-obesity drug. While some see potential in VKTX, other AI stocks may offer greater upside potential and less downside risk. For more information, check out our free report on the best short-term AI stock.

Read more at Yahoo Finance: Jim Cramer Recommends Eli Lilly Over Viking Therapeutics